399 related articles for article (PubMed ID: 33324011)
21. Interferon-gamma contributes to disease progression in the Ndufs4(-/-) model of Leigh syndrome.
Hanaford AR; Khanna A; James K; Truong V; Liao R; Chen Y; Mulholland M; Kayser EB; Watanabe K; Hsieh ES; Sedensky M; Morgan PG; Kalia V; Sarkar S; Johnson SC
Neuropathol Appl Neurobiol; 2024 Jun; 50(3):e12977. PubMed ID: 38680020
[TBL] [Abstract][Full Text] [Related]
22. mTOR inhibitors may benefit kidney transplant recipients with mitochondrial diseases.
Johnson SC; Martinez F; Bitto A; Gonzalez B; Tazaerslan C; Cohen C; Delaval L; Timsit J; Knebelmann B; Terzi F; Mahal T; Zhu Y; Morgan PG; Sedensky MM; Kaeberlein M; Legendre C; Suh Y; Canaud G
Kidney Int; 2019 Feb; 95(2):455-466. PubMed ID: 30471880
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of the mTOR pathway in abdominal aortic aneurysm: implications of smooth muscle cell contractile phenotype, inflammation, and aneurysm expansion.
Li G; Qin L; Wang L; Li X; Caulk AW; Zhang J; Chen PY; Xin S
Am J Physiol Heart Circ Physiol; 2017 Jun; 312(6):H1110-H1119. PubMed ID: 28213405
[TBL] [Abstract][Full Text] [Related]
24. Microglial response promotes neurodegeneration in the Ndufs4 KO mouse model of Leigh syndrome.
Aguilar K; Comes G; Canal C; Quintana A; Sanz E; Hidalgo J
Glia; 2022 Nov; 70(11):2032-2044. PubMed ID: 35770802
[TBL] [Abstract][Full Text] [Related]
25. Cyclopamine and Rapamycin Synergistically Inhibit mTOR Signalling in Mouse Hepatocytes, Revealing an Interaction of Hedgehog and mTor Signalling in the Liver.
Spormann L; Rennert C; Kolbe E; Ott F; Lossius C; Lehmann R; Gebhardt R; Berg T; Matz-Soja M
Cells; 2020 Jul; 9(8):. PubMed ID: 32751882
[TBL] [Abstract][Full Text] [Related]
26. A study of sirolimus and mTOR kinase inhibitor in a hypomorphic
Holditch SJ; Brown CN; Atwood DJ; Lombardi AM; Nguyen KN; Toll HW; Hopp K; Edelstein CL
Am J Physiol Renal Physiol; 2019 Jul; 317(1):F187-F196. PubMed ID: 31042058
[TBL] [Abstract][Full Text] [Related]
27. Ndufs4 knockout mouse models of Leigh syndrome: pathophysiology and intervention.
van de Wal MAE; Adjobo-Hermans MJW; Keijer J; Schirris TJJ; Homberg JR; Wieckowski MR; Grefte S; van Schothorst EM; van Karnebeek C; Quintana A; Koopman WJH
Brain; 2022 Mar; 145(1):45-63. PubMed ID: 34849584
[TBL] [Abstract][Full Text] [Related]
28. Double inhibition of cAMP and mTOR signalling may potentiate the reduction of cell growth in ADPKD cells.
de Stephanis L; Bonon A; Varani K; Lanza G; Gafà R; Pinton P; Pema M; Somlo S; Boletta A; Aguiari G
Clin Exp Nephrol; 2017 Apr; 21(2):203-211. PubMed ID: 27278932
[TBL] [Abstract][Full Text] [Related]
29. Effects of clofibrate and KH176 on life span and motor function in mitochondrial complex I-deficient mice.
Frambach SJCM; van de Wal MAE; van den Broek PHH; Smeitink JAM; Russel FGM; de Haas R; Schirris TJJ
Biochim Biophys Acta Mol Basis Dis; 2020 Jun; 1866(6):165727. PubMed ID: 32070771
[TBL] [Abstract][Full Text] [Related]
30. mTOR pathway inhibitors in cancer therapy: moving past rapamycin.
Wacheck V
Pharmacogenomics; 2010 Sep; 11(9):1189-91. PubMed ID: 20860456
[No Abstract] [Full Text] [Related]
31. Rapamycin, a mTOR inhibitor, induced growth inhibition in retinoblastoma Y79 cell via down-regulation of Bmi-1.
Wang YD; Su YJ; Li JY; Yao XC; Liang GJ
Int J Clin Exp Pathol; 2015; 8(5):5182-8. PubMed ID: 26191215
[TBL] [Abstract][Full Text] [Related]
32. Compensatory Increase of Transglutaminase 2 Is Responsible for Resistance to mTOR Inhibitor Treatment.
Cao J; Huang W
PLoS One; 2016; 11(2):e0149388. PubMed ID: 26872016
[TBL] [Abstract][Full Text] [Related]
33. Succination is Increased on Select Proteins in the Brainstem of the NADH dehydrogenase (ubiquinone) Fe-S protein 4 (Ndufs4) Knockout Mouse, a Model of Leigh Syndrome.
Piroli GG; Manuel AM; Clapper AC; Walla MD; Baatz JE; Palmiter RD; Quintana A; Frizzell N
Mol Cell Proteomics; 2016 Feb; 15(2):445-61. PubMed ID: 26450614
[TBL] [Abstract][Full Text] [Related]
34. mTOR kinase inhibitors as a treatment strategy in hematological malignancies.
Grzybowska-Izydorczyk O; Smolewski P
Future Med Chem; 2012 Mar; 4(4):487-504. PubMed ID: 22416776
[TBL] [Abstract][Full Text] [Related]
35. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J
PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608
[TBL] [Abstract][Full Text] [Related]
36. Iron status influences mitochondrial disease progression in Complex I-deficient mice.
Kelly CJ; Couch RK; Ha VT; Bodart CM; Wu J; Huff S; Herrel NT; Kim HD; Zimmermann AO; Shattuck J; Pan YC; Kaeberlein M; Grillo AS
Elife; 2023 Feb; 12():. PubMed ID: 36799301
[TBL] [Abstract][Full Text] [Related]
37. Rescue of cell death and inflammation of a mouse model of complex 1-mediated vision loss by repurposed drug molecules.
Yu AK; Datta S; McMackin MZ; Cortopassi GA
Hum Mol Genet; 2017 Dec; 26(24):4929-4936. PubMed ID: 29040550
[TBL] [Abstract][Full Text] [Related]
38. Beneficial Effects of Early mTORC1 Inhibition after Traumatic Brain Injury.
Nikolaeva I; Crowell B; Valenziano J; Meaney D; D'Arcangelo G
J Neurotrauma; 2016 Jan; 33(2):183-93. PubMed ID: 26122481
[TBL] [Abstract][Full Text] [Related]
39. Targeted therapy in sarcomas: mammalian target of rapamycin inhibitors from bench to bedside.
Vincenzi B; Napolitano A; D'Onofrio L; Frezza AM; Silletta M; Venditti O; Santini D; Tonini G
Expert Opin Investig Drugs; 2011 Dec; 20(12):1685-705. PubMed ID: 22010859
[TBL] [Abstract][Full Text] [Related]
40. Hypoxia treatment reverses neurodegenerative disease in a mouse model of Leigh syndrome.
Ferrari M; Jain IH; Goldberger O; Rezoagli E; Thoonen R; Cheng KH; Sosnovik DE; Scherrer-Crosbie M; Mootha VK; Zapol WM
Proc Natl Acad Sci U S A; 2017 May; 114(21):E4241-E4250. PubMed ID: 28483998
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
